Everything you care about in one place

Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.

Get Feeder

newsroom.regeneron.com

Regeneron Pharmaceuticals Inc. News Releases

Get the latest updates from Regeneron Pharmaceuticals Inc. News Releases directly as they happen.

Follow now 139 followers

Latest posts

Last updated 6 days ago

Regeneron Announces the 2025 Winners of the Regeneron Prize for Creative Innovation

6 days ago

TARRYTOWN, N.Y. , July 24, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals...

Lynozyfic™ (linvoseltamab-gcpt) Receives FDA Accelerated Approval for Treatment of Relapsed or Refractory Multiple Myeloma

28 days ago

TARRYTOWN, N.Y. , July 02, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc...

Regeneron to Report Second Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on August 1, 2025

about 1 month ago

TARRYTOWN, N.Y. , June 26, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc...

Regeneron Announces First-of-its-Kind Donation Matching Program with Independent Charitable Patient Assistance Organization

about 1 month ago

Initiative aims to expand and encourage philanthropy to help patients with retinal...

Dupixent® (dupilumab) Approved in the U.S. as the Only Targeted Medicine to Treat Patients with Bullous Pemphigoid (BP)

about 1 month ago

Approval based on pivotal results showing improvements in sustained disease remission and...

Dupixent® (dupilumab) Data at Revolutionizing Atopic Dermatitis (RAD) Conference Reinforce Use in Atopic Dermatitis Patients with Skin of Color

about 2 months ago

Atopic dermatitis is a chronic disease that disproportionately impacts communities of color...

Regeneron Expands Clinical-Stage Obesity Portfolio with Strategic In-Licensing of Novel Dual GLP-1/GIP Receptor Agonist

about 2 months ago

New licensing agreement with Hansoh Pharma provides Regeneron with HS-20094, a GLP-1/GIP...

Itepekimab Met Primary Endpoint in One of Two Chronic Obstructive Pulmonary Disease (COPD) Phase 3 Trials

2 months ago

AERIFY-1 trial met the primary endpoint of a statistically significant reduction in...